Treatment of MRSA-Positive Skin Wound in a 67-Year-Old Male Without Systemic Signs
For a 67-year-old male with an MRSA-positive wound and no systemic signs of infection, incision and drainage (if a drainable collection exists) is the primary treatment, with oral antibiotics added only if specific risk factors are present—otherwise, drainage alone may be sufficient. 1, 2
Primary Treatment Decision: Drainage vs. Antibiotics
The single most important intervention is determining whether a drainable purulent collection (abscess, furuncle, carbuncle) exists:
If a drainable abscess is present, incision and drainage (I&D) is the definitive primary treatment and may be adequate without antibiotics in an otherwise healthy patient with a simple abscess and no surrounding cellulitis 1, 2.
Antibiotics should be added to I&D when any of the following risk factors are present:
- Extensive surrounding cellulitis (erythema extending >5 cm from the abscess) 1, 2
- Multiple infection sites 2
- Systemic inflammatory response (fever >38°C, heart rate >90 bpm, respiratory rate >24 breaths/min) 1, 2
- Comorbidities or immunosuppression (diabetes, HIV/AIDS, malignancy) 2
- Extremes of age 2
- Abscess in difficult-to-drain areas (face, hands, genitalia) 2
- Lack of clinical response to drainage alone 2
- Rapidly progressive or extensive disease 2
Oral Antibiotic Regimens for MRSA (When Indicated)
When antibiotics are warranted, choose one of the following oral regimens for 5–10 days, individualized based on clinical response:
First-Line Options
Trimethoprim-sulfamethoxazole (TMP-SMX) 1–2 double-strength tablets twice daily provides excellent MRSA coverage but has limited activity against β-hemolytic streptococci, so it should be combined with a beta-lactam (e.g., cephalexin) if non-purulent cellulitis is also present 1, 2.
Doxycycline 100 mg twice daily is effective for MRSA but must be combined with a beta-lactam for typical cellulitis because it lacks reliable streptococcal coverage; it is contraindicated in children <8 years 1, 2.
Clindamycin 300–450 mg every 6–8 hours provides single-agent coverage for both MRSA and streptococci, making it ideal when both pathogens are concerns, but should only be used when local MRSA clindamycin resistance is <10% 1, 2.
Alternative Option
- Linezolid 600 mg twice daily is highly effective with no cross-resistance to other antibiotic classes, but its high cost and potential for bone marrow suppression (especially with treatment >14 days) limit its use to serious infections or when other options fail 2, 3, 4.
Treatment Duration
Treat for 5–10 days for most MRSA skin infections, with duration individualized based on clinical response 2.
Complicated infections may require 7–14 days 2.
For uncomplicated cellulitis, a 5-day course is sufficient if clinical improvement (resolution of warmth, tenderness, improving erythema, afebrile) is observed; extend only if symptoms persist 1, 5.
When Hospitalization and IV Therapy Are Required
Admit the patient and initiate intravenous antibiotics if any of the following are present:
- Systemic inflammatory response syndrome (fever, tachycardia, hypotension, altered mental status) 1, 2
- Signs of deeper or necrotizing infection (severe pain out of proportion, skin anesthesia, rapid progression, "wooden-hard" tissue, gas or bullae) 1
- Severe immunocompromise or neutropenia 1
- Failure of outpatient therapy after 24–48 hours 1
Intravenous MRSA-active regimens (A-I level evidence):
- Vancomycin 15–20 mg/kg IV every 8–12 hours (target trough 15–20 mg/L) 1, 5, 2, 6
- Linezolid 600 mg IV twice daily 5, 2, 3
- Daptomycin 4 mg/kg IV once daily 5, 2, 6
- Clindamycin 600 mg IV every 8 hours (only if local MRSA resistance <10%) 5, 2
Critical Pitfalls to Avoid
Do not prescribe beta-lactams alone (cephalexin, dicloxacillin, amoxicillin) for confirmed MRSA infections, as they lack MRSA activity 1, 2.
Do not use TMP-SMX or doxycycline as monotherapy for typical non-purulent cellulitis, as they do not reliably cover streptococci 1, 2.
Do not prescribe antibiotics without performing I&D when a drainable abscess is present—drainage is the cornerstone of therapy 1, 2.
Do not use rifampin as a single agent or adjunctive therapy for MRSA skin infections 2.
Obtain cultures from the wound to confirm MRSA and guide susceptibility testing 2, 6.
Adjunctive Measures
Elevate the affected extremity above heart level for at least 30 minutes three times daily to promote gravity drainage of edema 1, 5.
Address predisposing conditions such as venous insufficiency, lymphedema, chronic edema, obesity, and eczema to reduce recurrence risk 1, 5.
For recurrent MRSA infections, consider a 5-day decolonization regimen with intranasal mupirocin twice daily, daily chlorhexidine washes, and daily decontamination of personal items 1.